GlassScriptPhysician profile
William V Tomlinson
NPI 1265491203
$4,429.19
in general payments reported to CMS, 2019-2025
62 companies · $515 in 2025
The $515 reported for 2025 was more than what 75% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $463 · 2021: $589 · 2022: $859 · 2023: $696 · 2024: $674 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,885.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $467.61 | 2019-2025 | |
| Eisai INC. | $301.70 | 2019-2025 | |
| Boston Scientific Corporation | $281.98 | 2019-2025 | Spaceoar Vue System - 10ml, Spaceoar System |
| Astrazeneca Pharmaceuticals LP | $256.20 | 2019-2025 | Calquence, Enhertu, Tagrisso |
| Novartis Pharmaceuticals Corporation | $221.07 | 2019-2025 | |
| Seagen INC. | $168.63 | 2019-2023 | Padcev |
| Amgen INC. | $160.03 | 2019-2022 | |
| Janssen Biotech, INC. | $148.81 | 2019-2025 | Erleada |
| Incyte Corporation | $139.41 | 2019-2025 | Monjuvi, Zynyz, Pemazyre |
| Taiho Oncology, INC. | $128.32 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $119.74 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $117.70 | 2021-2023 | Libtayo |
| Daiichi Sankyo INC. | $115.77 | 2020-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $106.85 | 2021-2025 | Keytruda |
| Celgene Corporation | $101.91 | 2019-2025 | Reblozyl |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Tomlinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.